Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Silverback Therapeutics Inc (NASDAQ:SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab).
- Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).
- As of August, 40 patients with advanced or metastatic HER2-expressing or amplified solid tumors were enrolled in the trial.
- The most frequent treatment-related adverse events included injection site reactions, fever and chills, hypotension, nausea, vomiting, and fatigue.
- These mainly were mild or moderate, and severe/serious adverse events were reported.
- At higher dose levels, dose-limiting toxicities (DLTs) were observed, including Grade 3 hypotension, injection site reaction, fever, and hypoxia. These DLTs were resolved with supportive care.
- Mild or moderate Cytokine release syndrome (CRS) was observed.
- Early signals of anti-tumor activity were observed in a heavily pre-treated, heterogeneous population.
- Among 18 evaluable patients, one with HER2 IHC 2+ NSCLC had a confirmed partial response maintained at the most recently available scan obtained at 36 weeks post-enrollment and eight weeks after discontinuing study treatment.
- In addition, stable disease was reported in seven patients.
- Price Action: SBTX shares traded lower by 13.80% at $14 premarket on the last check Thursday.
- Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!